[EN] BICYCLIC DERIVATIVES AND USE THEREOF [FR] DÉRIVÉS BICYCLIQUES ET LEUR UTILISATION
摘要:
A compound of Formula (I), (II) or (III), stereoisomer thereof, pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the stereoisomer are disclosed.
[EN] BICYCLIC DERIVATIVES AND USE THEREOF [FR] DÉRIVÉS BICYCLIQUES ET LEUR UTILISATION
摘要:
A compound of Formula (I), (II) or (III), stereoisomer thereof, pharmaceutically acceptable salt thereof, pharmaceutically acceptable salt of the stereoisomer are disclosed.
[EN] BIFUNCTIONAL MOLECULES CONTAINING AN E3 UBIQUITINE LIGASE BINDING MOIETY LINKED TO A BCL6 TARGETING MOIETY<br/>[FR] MOLÉCULES BIFONCTIONNELLES CONTENANT UNE FRACTION DE LIAISON À L'UBIQUITINE LIGASE E3 LIÉE À UNE FRACTION CIBLANT BCL6
申请人:ARVINAS OPERATIONS INC
公开号:WO2021077010A1
公开(公告)日:2021-04-22
Bifunctional compounds, which find utility as modulators of B-cell lymphoma 6 protein (BCL6; target protein), are described herein. In particular, the bifunctional compounds of the present disclosure contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand that binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The bifunctional compounds of the present disclosure exhibit a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME
申请人:Hopper Allen
公开号:US20110092475A1
公开(公告)日:2011-04-21
The present invention provides 2-substituted-ethynylthiazole derivatives of formula (I):
wherein R
1
, R
2
and X are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods of using same.
TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS
申请人:Allen Shelley
公开号:US20110144085A1
公开(公告)日:2011-06-16
Compounds of Formula (I), in which A, B, R
1
, R
1a
, R
2
, R
3
, R
4
, R
5
, R
6
, and R
7
have the meanings given in the specification, are receptor tyrosine inhibitors useful in the treatment of immune cell-associated diseases and disorders, such as inflammatory and autoimmune diseases.
Heterocyclic compounds useful as Pim kinase inhibitors
申请人:Incyte Corporation
公开号:US10450296B2
公开(公告)日:2019-10-22
The present application is concerned with heterocyclic compounds that inhibit the activity of Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancers and other diseases.
Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
申请人:Nurix Therapeutics, Inc.
公开号:US11530229B2
公开(公告)日:2022-12-20
Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.